Overview
What is The Bluefield Project To Cure Frontotemporal Dementia?
The Bluefield Project is a nonprofit organization, established by a family group affected by Frontotemporal Dementia (FTD), with a mission to discover a cure for this debilitating condition. Located in San Francisco, California, the organization primarily focuses on funding research related to FTD. By privately funding basic, translational, and clinical studies, The Bluefield Project has boosted the number of labs dedicated to FTD research. The Consortium for Frontotemporal Dementia Research, partially financed by The Bluefield Project, employs a business-like approach to research, encouraging data and reagent sharing to expedite discoveries. FTD is a neurodegenerative condition that affects decision-making abilities, control of behavior, emotion, and language, making it the second most common early-onset dementia after Alzheimer's disease. This dedicated organization is committed to alleviating the impact of FTD on affected individuals and families.
Official website here: www.bluefieldproject.org
What are the reviews and ratings of this charity?
Charity Navigator Rating: 96% (Four-Star out of Four Stars)
The Bluefield Project To Cure Frontotemporal Dementia has earned a Four-Star rating from Charity Navigator, reflecting its strong performance in the area of accountability and finance. The charity achieved a remarkable score of 96% in this category, demonstrating high standards in financial management and transparency, which are crucial for donor confidence and support.
The organization is commended for its strong governance practices, with 62% of its board members being independent, which enhances objectivity in decision-making. Additionally, it maintains strict policies regarding conflict of interest and whistleblowing, ensuring ethical operations. The low liabilities to assets ratio further illustrates a sound financial position, indicating that the charity is effectively managing its resources.
While the data shows a strong commitment to financial accountability, specific programmatic outcomes or beneficiary feedback are not highlighted. This could provide a more comprehensive understanding of the charity’s impact beyond financial metrics. Overall, The Bluefield Project demonstrates excellent fiscal responsibility and governance, making it a trustworthy option for donors interested in supporting research and initiatives related to frontotemporal dementia.
This AI summary has been generated from information found on Charity Navigator.
Is The Bluefield Project To Cure Frontotemporal Dementia legitimate?
The Bluefield Project To Cure Frontotemporal Dementia is a legitimate nonprofit organization registered as a 501(c)(3) entity. The Bluefield Project To Cure Frontotemporal Dementia submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $368,000
Professional Fundraising Fees: $0
Other Salaries and Wages: $350,850
For more financial information, click here
Official website here: www.bluefieldproject.org
What is the mission statement of The Bluefield Project To Cure Frontotemporal Dementia?
The Bluefield Project To Cure Frontotemporal Dementia is an organization with a mission to find a cure for Frontotemporal Dementia (FTD). Established by a family group whose lives have been impacted by the condition, the project primarily focuses on funding FTD-related research. The organization has significantly increased the number of labs studying FTD through private funding of basic, translational, and clinical research. The Consortium for Frontotemporal Dementia Research, funded in part by The Bluefield Project, employs a unique approach to research by incentivizing data and reagent sharing, thereby accelerating discovery. The ultimate goal of The Bluefield Project is to combat FTD, a clinical syndrome characterized by degeneration of the frontal and temporal lobes, which is the second most common early-onset dementia after Alzheimer's disease.
Official website here: www.bluefieldproject.org
Who is the CEO of The Bluefield Project To Cure Frontotemporal Dementia?
Robin Richards Donohoe is the Board Chair of The Bluefield Project To Cure Frontotemporal Dementia.
Official website here: www.bluefieldproject.org
What is the revenue of The Bluefield Project To Cure Frontotemporal Dementia?
The Bluefield Project To Cure Frontotemporal Dementia's revenue in 2022 was $2,859,465.
Official website here: www.bluefieldproject.org
Who are the executives of The Bluefield Project To Cure Frontotemporal Dementia and what are their salaries?
The average compensation at The Bluefield Project To Cure Frontotemporal Dementia during 2022 was $239,617. There are 3 employees and 5 volunteers at The Bluefield Project To Cure Frontotemporal Dementia.
Here are 10 key members and their salaries:
- Compensation: $370,115
- Related: $0
- Other: $0
- Compensation: $368,000
- Related: $0
- Other: $0
- Compensation: $262,972
- Related: $0
- Other: $0
- Compensation: $125,500
- Related: $0
- Other: $0
- Compensation: $10,000
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Official website here: www.bluefieldproject.org
Where can I find the form 990 for The Bluefield Project To Cure Frontotemporal Dementia?
The Bluefield Project To Cure Frontotemporal Dementia's most recent form 990 was submitted in 2022 and can be accessed here.
Official website here: www.bluefieldproject.org
Learn more at the official website: www.bluefieldproject.org
Mission Statement of The Bluefield Project To Cure Frontotemporal Dementia
The Bluefield Project, a nonprofit organization established by a family deeply affected by Frontotemporal Dementia (FTD), is committed to spearheading the quest for a cure for this debilitating condition. FTD is a clinical syndrome that arises from the degeneration of the frontal lobe of the brain, potentially extending to the temporal lobe. This disorder is the second most prevalent early-onset dementia, surpassed only by Alzheimer's disease.
Recognizing the urgent need for research and advancements in the field, The Bluefield Project has taken an active role in funding FTD-related studies. By privately financing basic, translational, and clinical research, this organization has significantly expanded the number of laboratories dedicated to FTD research. One such initiative is the Consortium for Frontotemporal Dementia Research, which The Bluefield Project supports in part. This consortium employs a unique business model, incentivizing the sharing of data and reagents among researchers. This collaborative approach accelerates the discovery process, bringing researchers and resources together to tackle FTD more effectively.
In essence, The Bluefield Project's mission is to drive progress in the understanding and treatment of Frontotemporal Dementia. By funding research and promoting collaboration, the organization aims to find a cure for this devastating condition and improve the lives of those affected by it.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
The Bluefield Project To Cure Frontotemporal Dementia significantly impacts the landscape of research and treatment for frontotemporal dementia (FTD). By providing funding for FTD-related research, this initiative has greatly increased the number of laboratories dedicated to exploring this challenging condition. The establishment of the Consortium for Frontotemporal Dementia Research, partially funded by Bluefield, promotes a collaborative research model that encourages the sharing of data and resources among scientists. This approach accelerates discovery and facilitates advancements in understanding the complexities of FTD.
Frontotemporal dementia is a clinical syndrome resulting from the degeneration of the frontotemporal lobes, leading to debilitating effects on decision-making, behavior, emotion, and language capabilities. As the second most common form of early-onset dementia after Alzheimer’s disease, FTD presents unique challenges to patients and their families. The Bluefield Project's focus on fostering innovative research efforts is crucial in the pursuit of effective treatments and a potential cure, ultimately improving the quality of life for those affected by FTD.
This information is meant to be a general summary of The Bluefield Project To Cure Frontotemporal Dementia. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Investment Income: $1,413,677
- Program Service Revenue: $522
- Gross Receipts: $2,859,465
Assets and Liabilities:
- Total Assets: $29,690,825
- Total Liabilities: $355,873
- Net Assets: $29,334,952
Want to help this charity, for free? You can click here to learn more about Give Freely
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
Program fees
Revenue
$522
Organization Details
Founding Year
2010
Phone
(415) 626-1501Principal Officer
Robin Richards Donohoe
Main Address
637 Carolina Street, San Francisco, CA, 94107
Website
www.bluefieldproject.orgNTEE Category
Code: G48 - Disease
If you are a representative of The Bluefield Project To Cure Frontotemporal Dementia and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.